Vascular endothelial growth factor gene therapy - Biosidus S.A.

Drug Profile

Vascular endothelial growth factor gene therapy - Biosidus S.A.

Alternative Names: VEGF GENE Therapy - Biosidus S.A.

Latest Information Update: 28 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biosidus S.A.
  • Class Cytokine genes; Gene therapies; Growth factors
  • Mechanism of Action Angiogenesis inducing agents; Gene transference; Vascular endothelial growth factor A stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Ischaemic heart disorders

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for phase-I development in Ischaemic-heart-disorders in Argentina (Intracardiac, Injection)
  • 21 Jan 2016 Phase-I development is ongoing in Argentina
  • 17 Sep 2013 Phase-I clinical trials in Ischaemic heart disorders in Argentina before 17 Sep 2013 (Intramyocardial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top